API

PO API Capsule | API Pharmaceutical Outsourcing

An active pharmaceutical ingredient (API) is defined in ICH Q7 as “any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body.”

Active pharmaceutical ingredients are distinguishable from inactive pharmaceutical ingredients, commonly known as excipients or formulation aids.

The European Medicines Agency, and the US FDA have adopted the ICH Q7 definition of APIs.

Many other terms are used interchangeably with API. They include:

  • active
  • bulk pharmaceutical chemical
  • drug substance
  • active principle (especially for natural extracts)
  • therapeutic ingredient

Filter

Hide Filter
  • Catalent Expert to Present on Clinical Distribution Supply Chain

    Wednesday, April 11, 2012
    Esther Sadler-Williams, Senior Director Strategic Alliance Development, Clinical Supply Services at Catalent Pharma Solutions will lead two discussions, “Around the World in 80 Ways: How to Ensure a Lean and Efficient Clinical Distribution Supply ... read more
  • INC Research Appoints Christopher Gaenzle as General Counsel

    Tuesday, April 10, 2012
    INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced Christopher L. Gaenzle has joined the Company as its general counsel. Gaenzle will be part of ... read more
  • Clinical Trials Roundtable

    Monday, March 26, 2012
    Late phase clinical research has become a growing focus for regulators, CROs and biopharmaceutical and medical device companies. Increasing requirements for long-term safety and effectiveness of data collection during the peri-approval and post-... read more
  • Tactical Versus Strategic Outsourcing: Are the Drivers the Same for Large, Medium, and Small Sponsor Companies?

    Monday, March 26, 2012
    In any venue where clinical development outsourcing is being discussed, sooner or later someone always seems to wonder aloud if small companies can get the same attention from their providers that large companies do. What’s intriguing about this ... read more
  • Aptuit LLC Names Stuart E. Needleman as President and Chief Operating Officer

    Thursday, March 15, 2012
    Greenwich, CT, March 15, 2012 - Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, Stuart E. Needleman has been named President and Chief Operating Officer of Aptuit LLC. Following the recent sale of the company’s Clinical ... read more
  • INC Research to Discuss Global Partnerships and Future Trends

    Tuesday, February 28, 2012
    INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, will discuss the evolution of clinical development outsourcing trends at the Partnerships(TM) in Clinical ... read more
  • Boehringer Ingelheim and Xencor Enter a Collaboration Agreement

    Tuesday, February 21, 2012
    Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal ... read more
  • Catalent Completes Acquisition of Clinical Trials Supplies Business of Aptuit LLC

    Friday, February 17, 2012
    Catalent Pharma Solutions today announced that it has completed the acquisition of the Clinical Trial Supplies business of Aptuit LLC. The acquisition substantially expands Catalent’s Development & Clinical Services business, transforming it into the... read more
  • Ockham Completes Acquisition of Nexus Oncology

    Thursday, February 16, 2012
    Ockham, a leading, global full-service contract research organization (CRO) with a focus in oncology, today announces it has completed the acquisition of Nexus Oncology. The transaction also provides Ockham with an institutional investment partner. read more
  • One Year On…Almac Doubles Analytical Capacity in US Headquarters

    Thursday, February 09, 2012
    Almac is pleased to announce the doubling of analytical capacity at its 240,000 sq. ft. North American Headquarters. The facility, built on a 40 acre site in Souderton, PA, north of Philadelphia, and occupied since 2010, delivers full-service, ... read more
  • INC Research Releases New White Paper

    Wednesday, February 08, 2012
    INC Research , LLC, a therapeutically focused clinical research organization (CRO) with a trusted process for delivering reliable results, today announced it has released a new white paper titled, "The Innovation Imperative: How CROs Are Driving The... read more
  • Pharma and Biotech Services

    Sunday, January 01, 2012
    Bachem is a technology-based biochemicals company providing full service to the pharma and biotech industry. Bachem specializes in the manufacture of peptides and complex organic molecules as APIs, as well as innovative biochemicals for research ... read more
  • Late-stage API Development, Manufacturing, and CMO Relations

    Sunday, January 01, 2012
    Late-stage Development and first manufacture represent critical phases for a new API. Outsourcing these complicated tasks adds an additional layer of complexity. Chemistry that has been of secondary importance becomes the highest priority and faces ... read more
  • Custom Peptide Synthesis and API Production

    Sunday, January 01, 2012
    American Peptide Company, Inc. (APC) offers comprehensive selections of pre-manufactured catalog peptides, custom synthesis, and GMP peptide Active Pharmaceutical Ingredients. Our California based manufacturing facilities offer synthesis services ... read more
  • Pediatric Drug Development

    Tuesday, November 01, 2011
    Pediatric research is ethically challenging, requiring protection of children from potentially harmful exposure while encouraging drug development and pediatric labeling. read more